Browse > Article

Effect of Exopolymers of Aureobasidium pullulans on Improving Osteoporosis Induced in Ovariectomized Mice  

SONG HEBOK (TG Biotech Research Institute, Kyungpook National University)
PARK DONG CHAN (TG Biotech Research Institute, Kyungpook National University)
DO GYUNG MIN (TG Biotech Research Institute, Kyungpook National University)
HWANG SEUNG-LARK (TG Biotech Research Institute, Kyungpook National University)
LEE WON KYU (TG Biotech Research Institute, Kyungpook National University)
KANG HEUN-SOO (Metabolic Engineering Laboratories)
PARK BOK-RYUN (Glucan Co., Bio 21 Center)
JANG HEE-JEONG (Glucan Co., Bio 21 Center)
SONG CHANG-WOO (Glucan Co., Bio 21 Center)
PARK EUI KYUN (Skeletal Diseases Genome Research Center, Biomedical Research Institute, Kyungpook National University Hospital)
KIM SHIN-YOON (Department of Orthopedic Surgery, Biomedical Research Institute, Kyungpook National University, Hospital)
HUH TAE-LIN (Kyungpook National University, Department of Genetic Engineering)
Publication Information
Journal of Microbiology and Biotechnology / v.16, no.1, 2006 , pp. 37-45 More about this Journal
Abstract
Treatment with exopolymers of Aureobasidium pullulans SM-2001 containing $\beta-1,3/1,6-glucan$ inhibited osteoclastogenesis of bone marrow stem cells in a co-culture system with calvariae osteoblastic cells. In addition, the treatment increased mineral deposition in osteoblastic cells. These two observations prompted us to evaluate whether the exopolymers could be used as an anti-osteoporotic agent, and efficacy of the exopolymers to prevent bone loss was compared with alendronate, a bisphosphonate, in ovariectomized mice prone to osteoporosis. Administration of the exopolymers to the ovariectomized mice resulted in improved effects on femur weight and histomorphometric changes of femur such as trabecular bone volume (TBV), trabecular bone thickness (TBT), and cortical bone thickness (CBT). In conclusion, the exopolymers treatment inhibited bone loss from osteoporosis induced by ovariectomy, and the effect was comparable to alendronate administration.
Keywords
exopolymers; Aureobasidium pullulans; osteoporosis; osteoclasts; osteoblasts;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By Web Of Science : 6  (Related Records In Web of Science)
연도 인용수 순위
1 Boivin, G. and P. J. Meunier. 2003. The mineralization of bone tissue: A forgotten dimension in osteoporosis research. Osteoporos. Int. 14 Suppl. 3: S19-24   DOI
2 Bone, H. G., D. Hosking, J. P. Devogelaer, J. R. Tucci, R. D. Emkey, R. P. Tonino, J. A. Rodriguez-Portales, R. W. Downs, J. Gupta, A. C. Santora, and U. A. Liberman. 2004. Alendronate phase III osteoporosis treatment study group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350: 1189-1199   DOI   ScienceOn
3 Boyle, W. J., W. S. Simonet, and D. L. Lacey. 2003. Osteoclast differentiation and activation. Nature 423: 337- 342   DOI   ScienceOn
4 Strewler, G. J. 2004. Decimal point-osteoporosis therapy at the 10-year mark. N. Engl. J. Med. 350: 1172-1174   DOI   ScienceOn
5 Yan, J., V. Vetvicka, Y. Xia, A. Coxon, M. C. Carroll, T. N. Mayadas, and G. D. Ross. 1999. Beta-glucan, a 'specific' biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J. Immunol. 163: 3045-3052
6 Yang, B. K., J.-B. Park, and C. H. Song. 2002. Hypolipidemic effect of exo-polymer produced in submerged mycelial culture of five different mushrooms. J. Microbiol. Biotechnol. 12: 957-961
7 McClung, M. R., R. D. Wasnich, D. J. Hosking, C. Christiansen, P. Ravn, M. Wu, A. M. Mantz, J. Yates, P. D. Ross, and A. C. Santora. 2004. Prevention of postmenopausal bone loss: Six-year results from the early postmenopausal intervention cohort study. J. Clin. Endocrinol. Metab. 89: 4879-4885   DOI
8 Levi, G., V. Geoffroy, G. Palmisano, and M. C. de Vernejoul. 2002. Bones, genes and fractures: Workshop on the genetics of osteoporosis: From basic to clinical research. EMBO Rep. 3: 22-26   DOI   ScienceOn
9 Udagawa, N., N. Takahashi, T. Akatsu, H. Tanaka, T. Sasaki, T. Nishihara, T. Koga, T. J. Martin, and T. Suda. 1990. Origin of osteoclasts: Mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA 87: 7260- 7264
10 Bell, N. H. 2001. Advances in the treatment of osteoporosis. Curr. Drug Targets Immune Endocr. Metabol. Disord. 1: 93-102   DOI
11 Sakai, A., S. Nishida, N. Okimoto, Y. Okazaki, T. Hirano, T. Norimura, T. Suda, and T. Nakamura. 1998. Bone marrow cell development and trabecular bone dynamics after ovariectomy in ddy mice. Bone 23: 443-451   DOI   ScienceOn
12 Lorden, J. F. and A. Caudle. 1986. Behavioral and endocrinological effects of single injections of monosodium glutamate in the mouse. Neurobehav. Toxicol. Teratol. 8: 509-519
13 Lauritzen, D. B., R. Balena, M. Shea, J. G. Seedor, A. Markatos, H. M. Le, B. C. Toolan, E. R. Myers, G. A. Rodan, and W. C. Hayes. 1993. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J. Bone Miner. Res. 8: 871-879   DOI   ScienceOn
14 Van Beek, E., E. Pieterman, L. Cohen, C. Lowik, and S. Papapoulos. 1999. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264: 108-111   DOI   ScienceOn
15 Kabir, M., J. M. Oppert, H. Vidal, F. Bruzzo, C. Fiquet, P. Wursch, G. Slama, and S. W. Rizkalla. 2002. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Metabolism 51: 819- 826   DOI   ScienceOn
16 Chappard, D., M. Petitjean, C. Alexandre, L. Vico, P. Minaire, and G. Riffat. 1991. Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts. J. Bone Miner. Res. 6: 673-680   DOI   ScienceOn
17 Hong, K. H., K. H. Jang, J. C. Lee, S. H. Kim, M. K. Kim, I. Y. Lee, S. M. Kim, Y. H. Lim, and S. A. Kang. 2005. Bacterial ${\beta}$-glucan exhibits potent hypoglycemic activity via decrease of serum lipids and adiposity, and increase of UCP mRNA expression. J. Microbiol. Biotechnol. 9: 826-831
18 Seo, H.-P., J.-M. Kim, H.-D. Shin, T.-K. Kim, H.-J. Chang, B.-R. Park, and J.-W. Lee. 2002. Production of ${\beta}$-1,3/1,6-glucan by Aureobasidium pullulans SM-2001. Korean J. Biotechnol. Bioeng. 17: 376-380
19 Stanford, C. M., P. A. Jacobson, E. D. Eanes, L. A. Lembke, and R. J. Midura. 1995. Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J. Biol. Chem. 270: 9420-9428   DOI   ScienceOn
20 Seedor, J. G., H. A. Quartuccio, and D. D. Thompson. 1991. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J. Bone Miner. Res. 6: 339- 346   DOI   ScienceOn
21 Teitelbaum, S. L. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508   DOI   ScienceOn
22 Zhang, F. L. and P. J. Casey. 1996. Protein prenylation: Molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65: 241-269   DOI   ScienceOn
23 Park, E. K., Y. E. Lee, J. Y. Choi, S. H. Oh, H. I. Shin, K. H. Kim, S. Y. Kim, and S. Kim. 2004. Cellular biocompatibility and stimulatory effects of calcium metaphosphate on osteoblastic differentiation of human bone marrow-derived stromal cells. Biomaterials 25: 3403-3411   DOI   ScienceOn
24 Rodan, G. A. and T. J. Martin. 2000. Therapeutic approaches to bone diseases. Science 289: 1508-1514   DOI
25 Tohamy, A. A., A. A. El-Ghor, S. M. El-Nahas, and M. M. Noshy. 2003. Beta-glucan inhibits the genotoxicity of cyclophosphamide, adriamycin and cisplatin. Mutat. Res. 541: 45-53   DOI
26 Kim, H. N., J. N. Lee, G. E. Kim, Y. M. Lee, C. H. Kim, and J. W. Sohn. 1999. Comparative study of immune-enhancing activity of crude and mannoprotein-free yeast-glucan preparations. J. Microbiol. Biotechnol. 9: 826-831